CJC-1295 vs Sermorelin: What the Research Actually Shows
Both peptides target the same receptor, but their pharmacology, evidence base, and regulatory histories are meaningfully different. Here's what the published data actually says.
Sermorelin is a 29-amino-acid fragment of endogenous growth hormone-releasing hormone with a documented FDA regulatory history under the brand name Geref, though that branded approval was voluntarily withdrawn in 2008 and research-chemical sermorelin carries no approval. CJC-1295 is a synthetic GHRH analog engineered for a much longer half-life, with a smaller human evidence base and no FDA approval in any form. Most of the mechanistic data supporting CJC-1295 comes from animal studies rather than controlled human trials, which is a meaningful limitation when comparing the two compounds.
How Each Peptide Works at the Receptor Level
Sermorelin is structurally identical to the first 29 amino acids of endogenous human GHRH. That fragment retains full binding activity at the GHRH receptor on pituitary somatotroph cells, stimulating the synthesis and pulsatile release of growth hormone. Because it mirrors a naturally occurring sequence, its activity is self-limiting: it works within the body's existing feedback loop, and GH release remains subject to somatostatin inhibition. The peptide clears quickly, with a plasma half-life measured in minutes.
CJC-1295 is a 30-amino-acid synthetic analog of GHRH engineered specifically to extend that short half-life. The version most commonly sold in research markets is CJC-1295 with DAC, where DAC stands for Drug Affinity Complex. The DAC modification allows the peptide to bind covalently to circulating albumin, which dramatically slows clearance. Published pharmacokinetic data from a 2006 study in the Journal of Clinical Endocrinology and Metabolism reported a half-life of approximately six to eight days in healthy adults, compared to minutes for native GHRH or sermorelin. A version without DAC, sometimes labeled Modified GRF 1-29, has a shorter half-life and a different pharmacokinetic profile, though it is frequently mislabeled in the research-chemical market.
The practical consequence of that half-life difference is that CJC-1295 with DAC produces a sustained elevation of GH and IGF-1 rather than a discrete pulse. Whether sustained elevation is preferable to pulsatile release is an open physiological question. The pulsatile pattern of endogenous GH secretion is thought to be relevant to receptor sensitivity and downstream signaling, and long-acting GHRH analogs may not fully replicate that pattern.
What Does the Human Evidence Base Look Like for Each?
Sermorelin has the deeper human evidence record of the two. It was studied in clinical trials beginning in the 1980s and 1990s, including work on GH deficiency in children and age-related GH decline in adults. A 1997 study published in the Journal of Clinical Endocrinology and Metabolism by Corpas et al. examined sermorelin acetate in older men and documented increases in IGF-1 levels. The branded pharmaceutical Geref received FDA approval for pediatric GH deficiency, meaning it passed the agency's efficacy and safety review for that specific indication before the manufacturer voluntarily withdrew it in 2008 for commercial reasons. Research-chemical sermorelin sold today is not that approved drug and carries no approval of its own.
CJC-1295 with DAC has a much thinner human evidence base. The most-cited human pharmacokinetic study is the 2006 paper by Jetté et al. in the Journal of Clinical Endocrinology and Metabolism, which enrolled 21 healthy adults and 21 adults with excess adiposity across multiple dose cohorts. That study documented dose-dependent increases in GH and IGF-1 and established the albumin-binding half-life, but it was a phase I pharmacokinetic study, not a trial designed to measure clinical outcomes. No large randomized controlled trials of CJC-1295 in humans have been published in the peer-reviewed literature as of this writing.
The evidence gap is significant. Sermorelin's human data includes safety monitoring from FDA-reviewed trials conducted under the Geref approval process. CJC-1295's human data is limited to a single small pharmacokinetic study. Most of what is known about CJC-1295's effects on body composition, muscle, and fat comes from rodent studies, which do not reliably predict human outcomes.
Regulatory Status: Where Do Both Compounds Stand?
The branded pharmaceutical sermorelin acetate, sold as Geref, held FDA approval for GH deficiency diagnosis and treatment in children. When Serono withdrew the product in 2008, the approval lapsed. Compounding pharmacies in the United States have continued to prepare sermorelin under section 503A of the Federal Food, Drug, and Cosmetic Act, though the FDA's position on compounded versions of withdrawn drugs has shifted over time and remains subject to ongoing regulatory interpretation. Research-chemical sermorelin sold by peptide vendors is a separate category and carries no approval.
CJC-1295 has no FDA approval in any form and no completed IND application on the public record. It is sold by research-chemical vendors under the disclaimer that it is for laboratory research only and not for human use. The FDA has taken enforcement actions against vendors selling unapproved peptides, and CJC-1295 has appeared on agency lists of bulk drug substances that may not be compounded. The regulatory posture on research peptides has changed repeatedly since 2020, so checking current FDA guidance directly is advisable for anyone tracking this area.
The key regulatory distinction between the two compounds is historical depth. Sermorelin has a documented approval and withdrawal record that researchers can trace through FDA archives. CJC-1295 has no comparable regulatory history, which means there is no agency-reviewed safety dataset attached to it.
How Do the Side Effect Profiles Compare in the Literature?
Sermorelin's side effect data comes partly from the clinical trial record that supported the Geref approval. Reported adverse effects in those studies included injection-site reactions, flushing, and headache. Because the compound acts through the body's existing feedback mechanisms, it does not bypass somatostatin suppression, which researchers have argued may limit the risk of GH excess compared to direct GH administration. That argument is mechanistic, not a guarantee of safety.
CJC-1295's adverse effect data in humans is limited to what was captured in the 2006 Jetté et al. pharmacokinetic study. That study reported generally mild adverse events including headache, flushing, and injection-site discomfort. The small sample size and short observation window mean the study was not powered to detect less common or longer-term adverse effects. Animal studies in rodents have not flagged major toxicity signals, but rodent data has well-known limitations for predicting human safety.
One theoretical concern specific to CJC-1295 is the sustained GH and IGF-1 elevation produced by the DAC modification. Chronically elevated IGF-1 is associated in epidemiological literature with certain health considerations, though causality in that literature is complex and contested. This is a preclinical and theoretical concern, not a documented clinical finding from CJC-1295 trials.
What Distinguishes These Two Compounds When You Read the Data Closely?
The most important distinction is evidence maturity. Sermorelin has decades of human pharmacology data, a completed regulatory review under Geref, and a documented adverse event profile from controlled trials. CJC-1295 has one small phase I pharmacokinetic study in humans and a body of preclinical rodent data. Treating those two evidence bases as equivalent would misrepresent what is actually known.
The second meaningful distinction is pharmacokinetic design intent. Sermorelin was developed to mimic the natural GHRH signal as closely as possible, preserving pulsatile GH release. CJC-1295 with DAC was engineered to do the opposite, extending GH and IGF-1 elevation over days. Whether that difference produces meaningfully different physiological outcomes in humans has not been tested in a head-to-head clinical trial.
A third distinction is market labeling accuracy. The research-chemical market frequently conflates CJC-1295 with DAC and Modified GRF 1-29, which are different compounds with different half-lives. Buyers reviewing certificates of analysis should confirm which sequence and modification they are actually receiving. Sermorelin's sequence is well-defined and easier to verify against published reference standards, which gives it a modest quality-control advantage in the current vendor environment.
Vetted vendors for research use
Our index screens vendor documentation against the checks in this review. We never accept payment for rank placement.
Frequently asked questions
Has CJC-1295 ever been tested in a human clinical trial?
One published human study exists: a 2006 phase I pharmacokinetic trial by Jetté et al. in the Journal of Clinical Endocrinology and Metabolism, enrolling 42 participants across healthy and overweight groups. It measured GH and IGF-1 changes and established the albumin-binding half-life of approximately six to eight days. No phase II or phase III trials measuring clinical outcomes have been published.
Why was sermorelin withdrawn from the market if it had FDA approval?
The manufacturer, Serono, voluntarily withdrew Geref in 2008 for commercial reasons, not because of safety findings or an FDA-initiated action. The withdrawal means the branded product is no longer sold, but it does not erase the clinical trial record or the regulatory review that supported the original approval. The FDA's documentation of that approval history remains accessible through agency archives.
Is Modified GRF 1-29 the same compound as CJC-1295?
No. Modified GRF 1-29 is a version of CJC-1295 without the Drug Affinity Complex modification. It has a much shorter half-life than CJC-1295 with DAC and a different pharmacokinetic profile. The two are frequently mislabeled or used interchangeably in the research-chemical market, which is a sourcing and verification problem buyers should account for when reviewing certificates of analysis from vendors.
Sources
Sources are listed most recent first. Cited studies are peer-reviewed unless noted.
- Jetté et al., 2005, Journal of Clinical Endocrinology and Metabolism Phase I human pharmacokinetic study of CJC-1295
- Corpas et al., 1997, Journal of Clinical Endocrinology and Metabolism Human study of sermorelin in older men
Educational and informational content only. This is not medical advice, diagnosis, or treatment. The compounds discussed are research compounds not approved by the FDA or any equivalent authority for human use outside prescribed contexts. Always consult a licensed clinician before any health decision.
